Judgment of the EU Court of Justice in AstraZeneca v Commission
On 6 December 2012, the EU Court of Justice dismissed AstraZeneca’s appeal of the General Court’s judgment in AstraZeneca v Commission. The Court of Justice affirmed the reasoning and holdings of the General Court and rejected all of AstraZeneca’s arguments, including its challenge to the General Court’s analysis of the definition of the relevant markets and the findings that AstraZeneca’s IP and regulatory strategies related to its product Losec constituted an abuse of a dominant position in violation of Article 102 TFEU. This judgment, from the EU’s highest court, solidifies the concept of an abuse of IP and regulatory procedures, and thus will come as a disappointment to many life science companies.
Click on the link above to download this Covington & Burling briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
Why register to The Lawyer
More relevant to you
News from The Lawyer
Analysis from The Lawyer
Footie and telecoms dominate our regular round-up of recent M&A activity, as the threat of rising interest rates kick-started activity among organisations.